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Stigma and the Social Burden of Neglected Tropical
Diseases
Mitchell G. Weiss*
Department of Public Health and Epidemiology, Swiss Tropical Institute, Basel, Switzerland
In a village in Uganda where onchocerciasis is endemic, a 25-
year-old woman responded to questions about a photograph of a
skin lesion presented with the story of a villager suffering from
characteristic dermatitis. She described her community’s experi-
ence as follows:
‘‘They are hiding their skin so that people cannot see them. I have not
heard of anyone who wants others to know about it. No one will allow
them to lead, and many people ignore them. They are considered
dangerous. People fear contact with them. I feel sorry for them. Even me,
I feared that from staying and meeting them we could get the disease …
They find it hard to marry, and marriages can break because of this
condition.’’
Introduction
Over the past half century, social stigma has become an
increasingly important topic for health social sciences. Among
neglected tropical diseases (NTDs), to which I restrict my attention
in this article, leprosy has been a major focus of stigma studies
from the outset. Other NTDs for which stigma is an important
consideration include onchocerciasis, lymphatic filariasis, plague,
Buruli ulcer, leishmaniasis, and Chagas disease. Public health
interest in stigma has been especially concerned with the social
burden it attaches to illness, as illustrated by the account presented
above. Stigma is also an important social determinant of the
effectiveness of disease control through its effect on help-seeking
and treatment adherence. Furthermore, stigma influences political
commitment to disease control. Although that is typically a
problem because stigma may encourage neglect, for agencies
committed to working on problems that matter, recognition of the
serious impact of stigma may encourage them to support disease
control. The recent histories of onchocerciasis and lymphatic
filariasis control, noted later in this article, illustrate this point.
The impact of stigma is not readily accounted for in the
epidemiological data that characterize the defined burden of
disease. Instead, stigma imposes what has been termed a ‘‘hidden
burden’’ [1]. Increasing health research interest in the topic is
indicated by the literature cited in Medline. The first citation
appeared in 1950, and there was no more than one citation in
seven of the next 15 years to 1964. With the publication of
Goffman’s seminal treatise on stigma in 1963 [2], many more
followed. Six citations, mostly concerned with mental health but
one with leprosy stigma, are listed for 1965, and there has not been
a year since then without a contribution to the health literature on
social stigma. In recent years, the number has increased sharply, to
458 in 2006 (Figure 1).
Here, I address key questions about how concepts of stigma
have changed over time. Who is affected, and how? What are the
relevant distinctions between stigma associated with culture-
specific meaning of a disease and with the social response to signs
and symptoms? Current interest in the topic aims to apply answers
to such questions in disease control to reduce the social burden of
NTDs. Ideally, practical health social science interest aims to
transform social stigma into social support. International health
experience with NTDs provides some examples, and I conclude
with a review of open questions for research.
Historical Concepts of Disease-Related Stigma
Leprosy has been a major interest of health-related stigma
studies from the outset. The second stigma citation in Medline
documented the consistency of the harsh impact of stigma on
people’s lives throughout the world in Africa, Asia, the Pacific
Islands, and the United States. Kellersberger in 1951 described the
mistreatment of people with leprosy, highlighting misinformation
that sparked fear of the disease, and tension between sensation-
alistic press accounts and efforts to promote responsible legislation
[3]. He attributed the social stigma of leprosy to a ‘‘fear of the
loathsome manifestations of the disease’’ and ‘‘superstitions which
call down a curse from some deity.’’
In presenting a social history of leprosy, Gussow and Tracy [4]
questioned the scientific validity of the so-called destigmatization
theory, which attributed stigma to historical, social, and medical
errors, including a misreading of biblical accounts. The theory—
which was promulgated by patients of the leprosy hospital in
Carville, Louisiana, in their newsletter—regarded stigma as worse
than the disease itself. It argued that correcting misconceptions
with scientific facts about the capacity to prevent and treat leprosy
would greatly reduce, if not eliminate, stigma. At that point,
however, in the sulfone era when so much was still unknown about
the spread and prevention of leprosy, and the capacity for effective
treatment was still limited, Gussow and Tracy [4] were skeptical
about whether the power of science was adequate to challenge
social stigma. Better science was needed for that.
They also argued that in addition to the cultural meaning of the
disease, discrediting (even racist) ideas about those who had it was
also an important factor maintaining social stigma. They make
that point with a rhetorical question: ‘‘What, it can be asked,
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might have been the status of leprosy had it been prevalent in
Europe and the United States, instead of being a disease of poor
people living in poor nations?’’ Their ensuing discussion indicates
how the social history of disease and stigma foreshadowed
arguments for establishing an international health focus on NTDs.
Goffman’s study of stigma reconceptualized the term with
reference to social interactions, deviance, and exclusion [2]. This
social formulation replaced archaic moralistic definitions that
disparaged persons marked by stigma, definitions that still persist
in modern dictionaries but ignore modern usage. Unlike current
public health practitioners, Goffman’s and other sociologists’ study
of stigma was primarily an academic interest. Health status was no
more than a subset of a broader collection of stigmatizing
conditions, and their interest was in social theory rather than social
policy or health policy. Other social science theories of stigma
have attempted to explain it as a product of labeling, mainly
concerned with mental illness, but Nancy Waxler’s analysis
focused on leprosy [5]. Labeling theory, which is concerned
mainly with discrimination and is relatively inattentive to other
aspects of stigma [6], provided a theoretical basis for a
controversial policy to rename leprosy as Hansen disease. Practical
concerns that have led to rethinking health and social policy
implications of stigma now emphasize the relevance of human
rights as a framework for stigma studies (Figure 2). Archaic
concepts that failed to question the blameworthiness or immorality
of stigmatized persons have now been replaced by consideration of
Figure 1. Medline Citations for Social Stigma (1965–2007). The annual number of citations for articles identified in a search for ‘‘stigma’’ as a
text word (i.e., in the title or abstract) and excluding references to usage as a botanical term.
doi:10.1371/journal.pntd.0000237.g001
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the immorality of unjustly denying civil rights and social
acceptance of people because of their health status.
Health social science interest in stigma considers its impact not
only on the experience and behavior of individuals but also on
disease control [7]. The rationale that motivates stigma for different
conditions includes a mix of cultural meaning, avoidance of socially
discomforting disfigurement and disability, and exaggerated fear of
danger and contagion. The relative influence of each of these factors
varies. For leprosy and plague, the cultural meaning of the disease is
an especially important feature of stigma. For other NTDs (e.g.,
onchocerciasis, lymphatic filariasis, Buruli ulcer, and leishmaniasis),
the response to symptoms and features of the illness, and unfounded
fear of contracting the condition, may operate in the absence of any
clear cultural historical meaning of illness.
Measuring stigma as a guide for policy is becoming an
increasing priority [8]. Although examples of stigma are often
clear and striking, assessment may nevertheless be ambiguous.
Some forms of discrimination are motivated by public health
considerations, rather than stigma (e.g., not accepting blood
donated by people with HIV). Someone excluded from a job
because they have a condition, even though that condition does
not prevent them from fulfilling the requirements of the position, is
in a different category with regard to social stigma from someone
who is excluded (removed or not hired) because they cannot fulfill
the requirements of the position. On the other hand, different rules
for compensation for disability from some diseases compared with
others may represent a manifestation of social stigma.
Identifying factors that maintain or challenge stigma should
guide efforts to mitigate its effect. Gussow and Tracy [4] argued
that to end or lessen the stigma of leprosy, it is essential to
understand its social history and current cultural meaning: ‘‘One
cannot hope to understand the adaptational problems of patients
without an understanding of the ‘world-view’ of the people
involved and their view of such concepts as health and illness’’ [4].
Stigma affects not only patients, but also families, groups,
communities and even nations, as illustrated by the ‘‘nationwide
panic and a near international isolation of India’’ that followed the
1994 disease outbreak alleged to be plague in Surat [9,10].
Different stigmatized conditions are also associated with
distinctive features of stigma. Responses to physical deformities
(e.g., edematous limbs or scrotum with lymphatic filariasis),
unacceptable scratching with onchodermatitis, exaggerated con-
cerns about the dangerousness of contagion, and moral condem-
nation that blames people with leprosy are all features of
condition-specific stigma. Such ideas about stigma appear to be
related to the experience, meaning, and behavior associated with
the disease among both affected persons and unaffected persons in
the community who have ideas about it and who may either
stigmatize or support affected persons.
Features and Implications of a Hidden-Distress
Model
Personal experience and childhood associations may perpetuate
stigmatizing social norms. Recollections of stigmatizing behavior
engender fear of an anticipated social response. For example, a
patient in Mumbai recently diagnosed with leprosy explained why
he was so upset by the term that named his condition, despite the
fact that his somatic symptoms were minimal: ‘‘My uncle has
leprosy. His fingers and toes are bent like this. He can’t eat or
drink himself. He stays in a separate hut in the village. People keep
away from him.’’ Such recollections lead to anticipated social
exclusion: ‘‘If people were to know, they might not talk to me
anymore. I would have to leave if they treated me like that. I
couldn’t take it’’ [11].
The social rejection experienced by this patient’s uncle and his
fear that he might be treated similarly have been distinguished in
Scambler’s hidden distress model [12]. It recognizes a difference
between actually experiencing discrimination or exclusion and
feeling it will happen. This distinction between enacted and felt
stigma may be further elaborated by differentiating anticipated
stigma (regarded as unjustified but likely) and internalized stigma. In
this sense, internalization refers to a process in which a person with
a stigmatized condition accepts perceived exclusionary views of
society and self-stigmatizes himself or herself (Figure 3).
Those who stigmatize others may do so directly or indirectly.
Stigmatizers may actively engage in the process of exclusion, using
their power to discriminate unfairly, ostracizing, or actively
troubling someone whom they regard to be unacceptable. Others
who do not actively engage in exclusion may endorse it, justifying
and supporting exclusion though they themselves refrain, owing to
legal or moral constraints. Still others may disagree with the
stigmatizing behavior of their family, friends, or colleagues, but
they nevertheless do nothing to stop it. They accept it without
endorsing it, either because they feel powerless to interrupt the
process, or because they feel vulnerable to stigma if they identify
themselves with the interests of others who are victimized.
Equating enacted stigma (a social concept) with discrimination
(which may have legal implications), Deacon and colleagues
further elaborate the relationship between different kinds of stigma
and discrimination [6].
Manifestations of stigma, whether experienced or perpetrated,
are usually situated either in a relatively more public or more
Figure 2. Alternative Formulations of Social Stigma.
doi:10.1371/journal.pntd.0000237.g002
Figure 3. Extending Scambler’s Hidden Distress Model of
Stigma [12] to Facilitate Strategic Interventions.
doi:10.1371/journal.pntd.0000237.g003
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private context. Public settings include schools, workplaces, and
clinical health services; more private settings include social
functions, family and household relations, and other interpersonal
interactions. Legal protection and codes of conduct may protect
people from enacted stigma in public settings or provide
compensation for discrimination. Widely publicized court-award-
ed compensation to people with leprosy incarcerated over many
years by the Government of Japan is an example [13]. Although
such measures directly address enacted stigma, they are also a
statement of values that may discourage endorsement and
acceptance of stigmatization (Figure 4).
Complementing legal protection, promotion of public aware-
ness of stigmatized health problems aims to challenge cultural
ideas that blame victims or legitimize exclusion. It also aims to
provide alternative explanations that correct exaggerated and
unfounded concerns about danger and risk. Individuals who have
internalized stigmatizing social views associated with their health
problems benefit from support challenging these views. Such help
may come from community or health care groups with a common
interest and experience, from advocacy groups, or from counseling
by health staff attentive to the social impact of stigmatizing illness.
International Health Experience with Stigma and
NTDs
The experience of international health projects concerned with
stigma indicates how the framework presented in Figure 4 relates to
local interventions. A multi-country study of onchodermatitis in
Cameroon, Ghana, Nigeria, Tanzania, and Uganda used cultural
epidemiological methods to examine gender-related features of the
impact of stigma. Cultural epidemiology examines the distribution of
categories and narrative context of illness experience, meaning, and
behavior. It is particularly concerned with how such features of illness
affect stigma, and effects on behavior relevant for disease control. The
study of villagers with onchocercal skin disease considered their
illness, and the study of unaffected residents in endemic communities
used vignettes with characteristic histories and photographs depicting
effects of the disease to assess the range and prominence of various
community views about the condition. The respondent’s account
quoted at the beginning of this article was extracted from one of these
studies. The approach permitted analysis of the experience and
meaning of illness (patterns of distress and perceived causes) that were
associated with either more or less stigma, and with gender-specific
features. Findings included distinctive qualitative features of stigma
for men and women. For example, men were more concerned about
limitations on their economic opportunities and women with the
social impact affecting prospects for marriage and family [14].
Stigma-related findings and other patterns of distress demon-
strated the severity of symptoms and substantial suffering that
resulted from itching, which might otherwise have been dismissed
as a relatively trivial symptom. Documenting the seriousness of the
condition and showing how many people were affected provided
justification that helped to establish the African Programme for
Onchocerciasis Control (APOC) [15]. Studies demonstrating the
impact of stigma on patients with lymphatic filariasis in Ghana
and Sri Lanka have also helped to document this aspect of the
hidden burden of that disease [16,17].
Addressing concerns about disability and internalized stigma
arising from lymphatic filariasis, a project funded by the
UNICEF/UNDP/World Bank/WHO Special Programme for
Research and Training in Tropical Diseases (TDR) developed
support groups in Haiti from 1998 to 2001 [18]. Disfiguring
features of elephantiasis accounted for observed stigma. Young
girls found it difficult to marry, and physical impairment interfered
with their earning capacity. These groups integrated social support
responsive to internalized stigma with practical advice and support
responsive to symptoms of the disease, e.g., providing assistance
for affected persons to obtain appropriate footwear. Experience
showing improved self-esteem, social relations, and quality of life
demonstrated the value of a group approach for integrating
interventions for social stigma with other aspects of community
support. The investigators suggested the approach also has
broader significance for other health problems [18].
Program efforts in India to reduce the stigma of leprosy have
also been integrated with broader interests of disease control [19].
Although we have noted that Gussow and Tracy’s experience in
the 1960s left them skeptical of the power of science to successfully
challenge stigma at the time, subsequent developments made that
question more compelling. Promoting the awareness of multidrug
treatment, introduced in the early 1980s, and making it available
also aimed to change ideas about leprosy that conflicted with a
medical model of a treatable disease. Public awareness campaigns
have focused on a simple message, that leprosy can be cured
(Figure 5), delivered with greater commitment and enthusiasm
than was possible when only dapsone therapy was available.
The campaign may be regarded as a response to a widely
appreciated need, articulated by Gussow and Tracy, ‘‘to make
leprosy ‘a disease just like any other’’’ [4]. They had argued that to do
so, efforts to change public attitudes should be integrated with
comprehensive scientific studies, ‘‘including basic scientific research,
and cross-cultural medical and social epidemiological studies’’ [4].
Pursuing that approach in India’s anti-leprosy campaign in the 1980s
obligated the health system to provide effective services to ensure that
Figure 4. Points of Intervention to Mitigate Stigmatizing and being Stigmatized.
doi:10.1371/journal.pntd.0000237.g004
www.plosntds.org 4 May 2008 | Volume 2 | Issue 5 | e237
the message ‘‘leprosy can be cured’’ was valid and credible. That
experience and a continuing challenge to coordinate biomedical and
social aspects of public health highlight the importance of integrating
the priority of reducing disease-related stigma and other priorities for
disease control.
A Way Forward
Although hypotheses about the impact of stigma are frequently
stated as proven fact, they nevertheless require testing. For
example, it is frequently asserted that stigma deters help-seeking
and interferes with adherence to treatment. That is true, but
anecdotal examples show that stigma may also encourage
treatment and promote adherence, so that a motivated patient
may become free of a condition that is more undesirable because
of stigma. Although that premise requires confidence that health
care can help, explanatory models and illness behavior within a
population also vary. We need to explain how social and cultural
factors account for such a range of behavior. At another level,
health policy studies need to consider how stigma influences
priorities, policymaking, and health system operations.
The framework presented here suggests a research agenda
appropriate for mixed-methods (qualitative and quantitative)
designs of cultural epidemiology and other approaches. I hope
that this framework and the experience I have reviewed may
usefully guide further studies and interventions among persons
with stigmatized conditions, unaffected persons in endemic
communities, and among policymakers. Ultimately, stigma
research encompasses an essential question that must be addressed
to explain why NTDs are neglected.
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for disease control.
2. Archaic models of stigma—moralistic and critical of
those who were stigmatized—have been supplanted by
social theories based on deviance and labeling, and
subsequently complemented by a formulation con-
cerned with the priority of human rights.
3. As a guide to research and policy, the hidden distress
model distinguishes enacted stigma from felt stigma. By
extending that model, felt stigma may be further
elaborated to distinguish anticipated stigma and inter-
nalized stigma.
4. Personal, social, health system, and policy-related inter-
ests in health-related stigma all aim to transform social
stigma into social support, each in their respective
domains and through means that are relevant for a
particular condition and setting.
5. Variations in the experience of stigma, its effects on
illness behavior, and the influence of illness explanatory
models may be clarified with mixed-methods designs of
cultural epidemiology and other approaches for useful
studies of stigma.
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